Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Signs Copromotion Deal With Chinese Manufacturer For Influenza Vaccine

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Chinese vaccine manufacturer Sinovac Biotech will copromote its influenza vaccine Anflu with GlaxoSmithKline (China) Investment Co. under an exclusive service agreement announced Aug. 1

You may also be interested in...



Sinovac Beefs Up R&D To Bring Vaccines Into Clinical Trials To Prepare For Healthcare Reform

SHANGHAI - Chinese vaccine maker Sinovac said it will invest heavily in R&D over the next three years to prepare for China's ongoing healthcare reforms and to reduce the impact of the global financial crisis, during a conference call with investors and analysts on April 9

Sinovac Beefs Up R&D To Bring Vaccines Into Clinical Trials To Prepare For Healthcare Reform

SHANGHAI - Chinese vaccine maker Sinovac said it will invest heavily in R&D over the next three years to prepare for China's ongoing healthcare reforms and to reduce the impact of the global financial crisis, during a conference call with investors and analysts on April 9

Sinovac To Start Clinical Trials For Hep A Vaccine In Ukraine; First Overseas Steps

SHANGHAI - Sinovac has inked a deal with Ukraine-based Biolik Biopharmaceutical to conduct clinical trials for its inactivated hepatitis A vaccine Healive in Ukraine, the company announced on Sept. 15

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel